Compare Amgen, Inc. (AMGN) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $16.42. The key difference: Amgen, Inc. pays a 2.77% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | PDBC | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $18.91 |
52-Week Low | $271.18 | $12.90 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PDBC trades at $16.44, up 0.12% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF has delivered strong returns, including a 37% gain since March 2024, outperforming the S&P 500. Recent news highlights its role as a diversified commodity strategy without K-1 tax forms, though momentum has weakened amid oil price declines and geopolitical tensions.
The outlook remains favorable for inflation hedging, but risks include commodity volatility and unpredictable distributions. Wall Street sentiment is mixed, with a recent downgrade to hold citing fading momentum. Key support sits at $16, with resistance at $17, indicating limited near-term upside without a breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
